Claims for Patent: 5,811,260

Summary for Patent: 5,811,260

Title:	Exogenous gene expression vector containing chick .beta.-actin gene promoter
Abstract:	An expression vector for the expression of an exogenous gene in an animal cell, which contains a chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene at the downstream of said promoter and a process for expressing an exogenous gene, which comprises incorporating said exogenous gene into the expression vector at the restriction enzyme site for incorporating the exogenous gene, introducing said vector into an animal cell and culturing the obtained transformed animal cell. The expression system of the present invention can be applied to an expression of any exogenous gene and has an extremely high expression efficiency and is applicable to a wide range of host cells, and hence can sufficiently be utilized for industrial-scale production of a useful material.
Inventor(s):	Miyazaki; Junichi (Kumamoto, JP), Yamamura; Ken-ichi (Kumamoto, JP), Araki; Masatake (Kumamoto, JP), Yonemura; Hiroshi (Kumamoto, JP), Nozaki; Chikateru (Kumamoto, JP)
Assignee:	Juridical Foundation The Chemo-Sero Therapeutic Research Institute (Kumamoto, JP)
Application Number:	07/373,143
Patent Claims:	1. An expression vector for the expression of an exogenous gene in an animal cell, which comprises a modified chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene downstream of said chick .beta.-actin gene promoter, wherein the modified chick .beta.-actin gene promoter is a hybrid promoter formed by incorporating a second promoter into an intron of said chick .beta.-actin gene promoter. 2. The expression vector of claim 1 wherein the 3' end of said chick .beta.-actin gene promoter contains a gene fragment of the original structural gene of .beta.-actin including at least the sequence up to the cytosine (C) located five base pairs upstream from the initiation codon (ATG) of said original structural gene of .beta.-actin. 3. The expression vector of claim 1 wherein said second promoter is a promoter derived from an SV 40 gene. 4. The expression vector of claim 3 wherein said second promoter is an SV 40 early promoter. 5. The expression vector of claim 1 wherein said second promoter is LTR of Rous sarcoma virus. 6. The expression vector of claim 3 which further contains an SV 40 early transcription splicing region and polyadenylation region. 7. The expression vector of claim 5 which further comprises the SV 40 replication origin (SV 40 ori). 8. A process for expressing an exogenous gene which comprises incorporating said exogenous gene into an expression vector for the expression of an exogenous gene in an animal cell, the expression vector comprising a modified chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene downstream of said chick .beta.-actin gene promoter, introducing said vector into an animal cell and culturing the resulting transformed cell, wherein the modified chick .beta.-actin gene promoter is a hybrid promoter formed by incorporating a second promoter into an intron of said .beta.-actin gene promoter. 9. The process of claim 8 wherein said expression vector further comprises an SV 40 early transcription splicing region and polyadenylation region. 10. The process of claim 9 wherein said expression vector further comprises the SV 40 replication origin (SV 40 ori). 11. The expression vector of claim 4 which further contains an SV 40 early transcription splicing region and polyadenylation region.

Details for Patent 5,811,260

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-09-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-09-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-09-22